Michelle Prickett

1.2k total citations
17 papers, 189 citations indexed

About

Michelle Prickett is a scholar working on Pulmonary and Respiratory Medicine, Otorhinolaryngology and Epidemiology. According to data from OpenAlex, Michelle Prickett has authored 17 papers receiving a total of 189 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 4 papers in Otorhinolaryngology and 4 papers in Epidemiology. Recurrent topics in Michelle Prickett's work include Cystic Fibrosis Research Advances (14 papers), Antibiotic Resistance in Bacteria (4 papers) and Sinusitis and nasal conditions (4 papers). Michelle Prickett is often cited by papers focused on Cystic Fibrosis Research Advances (14 papers), Antibiotic Resistance in Bacteria (4 papers) and Sinusitis and nasal conditions (4 papers). Michelle Prickett collaborates with scholars based in United States. Michelle Prickett's co-authors include Manu Jain, Joanne Cullina, Susanna A. McColley, Alan R. Hauser, Marc H. Scheetz, Serge Cremers, Sean N. Avedissian, Michael T. Yin, Nathaniel J. Rhodes and Christine J. Kubin and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Thorax and Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy.

In The Last Decade

Michelle Prickett

13 papers receiving 188 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michelle Prickett United States 7 92 76 67 37 37 17 189
Marie Dorda Germany 10 74 0.8× 194 2.6× 165 2.5× 10 0.3× 27 0.7× 18 334
Nicole Mayer‐Hamblett United States 8 61 0.7× 313 4.1× 80 1.2× 6 0.2× 89 2.4× 16 366
Amy Jaeger United States 6 79 0.9× 61 0.8× 87 1.3× 6 0.2× 210 5.7× 7 422
Zhiqiang Zhuo China 7 15 0.2× 46 0.6× 17 0.3× 5 0.1× 65 1.8× 25 158
Marcella Blackledge United States 5 34 0.4× 127 1.7× 97 1.4× 1 0.0× 40 1.1× 5 200
Mélanie Fromentin France 6 16 0.2× 30 0.4× 40 0.6× 4 0.1× 36 1.0× 9 139
Beth Hammer United States 4 9 0.1× 66 0.9× 67 1.0× 3 0.1× 61 1.6× 6 220
Liliana A González Chile 7 22 0.2× 33 0.4× 24 0.4× 4 0.1× 95 2.6× 9 176
Nobuko Maki Japan 6 32 0.3× 5 0.1× 41 0.6× 5 0.1× 75 2.0× 10 283
Michael Greiner Switzerland 6 14 0.2× 27 0.4× 20 0.3× 4 0.1× 61 1.6× 9 123

Countries citing papers authored by Michelle Prickett

Since Specialization
Citations

This map shows the geographic impact of Michelle Prickett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Prickett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Prickett more than expected).

Fields of papers citing papers by Michelle Prickett

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Prickett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Prickett. The network helps show where Michelle Prickett may publish in the future.

Co-authorship network of co-authors of Michelle Prickett

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Prickett. A scholar is included among the top collaborators of Michelle Prickett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Prickett. Michelle Prickett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Prickett, Michelle, et al.. (2025). MULTICENTER EXPERIENCE WITH FIRST-LINE INTRAVESICAL GEMCITABINE-DOCETAXEL VERSUS BACILLUS CALMETTE-GUERIN FOR HIGH-RISK NMBIC. Urologic Oncology Seminars and Original Investigations. 43(3). 85–85.
2.
Butcher, Jennifer, Christopher Siracusa, Robin S. Everhart, et al.. (2025). “Time out for an hour, every day, my whole life”: understanding treatment burden in cystic fibrosis in the era of Elexacaftor/Tezacaftor/Ivacaftor (ETI). Journal of Cystic Fibrosis. 24(6). 1130–1140.
3.
Maggs, Jill, G. Sawicki, Lisa Sweeney, et al.. (2024). Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study. Contemporary Clinical Trials. 148. 107752–107752. 1 indexed citations
4.
Schwartz, Brian S., Thanh‐Huyen T. Vu, David B. Conley, et al.. (2024). Associations Between Chronic Rhinosinusitis and the Development of Non–Cystic Fibrosis Bronchiectasis. The Journal of Allergy and Clinical Immunology In Practice. 12(11). 3116–3122.e2. 1 indexed citations
5.
Everhart, Robin S., Jill Maggs, Gregory S. Sawicki, et al.. (2024). What does it mean to be “healthy” when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study. Journal of Cystic Fibrosis. 24(1). 187–192. 1 indexed citations
6.
Vu, Thanh‐Huyen T., Whitney W. Stevens, Michelle Prickett, et al.. (2023). Antecedent chronic rhinosinusitis is a risk factor for the development of bronchiectasis. Journal of Allergy and Clinical Immunology. 151(2). AB202–AB202.
7.
Prickett, Michelle, Patrick A. Flume, Kathryn A. Sabadosa, Quynh T. Tran, & Bruce C. Marshall. (2022). Telehealth and CFTR modulators: Accelerating innovative models of cystic fibrosis care. Journal of Cystic Fibrosis. 22(1). 9–16. 11 indexed citations
8.
Vu, Thanh‐Huyen T., Whitney W. Stevens, Michelle Prickett, et al.. (2022). The Presence of Chronic rhinosinusitis (CRS) is Associated with Increased Healthcare Utilization in Patients with Asthma and Bronchiectasis (BE). Journal of Allergy and Clinical Immunology. 149(2). AB161–AB161. 2 indexed citations
9.
Peters, Anju T., Sumit Kumar Bose, Michelle Prickett, et al.. (2021). Prevalence of Bronchiectasis in Patients with Chronic Rhinosinusitis in a Tertiary Care Center. The Journal of Allergy and Clinical Immunology In Practice. 9(8). 3188–3195.e2. 19 indexed citations
10.
Prickett, Michelle, et al.. (2021). Adult-Onset Still’s Disease Presenting as Macrophage-Activation Syndrome With Critical Illness in the Third Trimester of Pregnancy: A Case Report. Critical Care Explorations. 3(5). e0440–e0440. 7 indexed citations
11.
Sala, Marc A., et al.. (2021). Looking toward the future: Approaching care of the aging CF patient. Pediatric Pulmonology. 57(S1). S113–S117. 6 indexed citations
12.
Avedissian, Sean N., Christine J. Kubin, Nathaniel J. Rhodes, et al.. (2018). Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 38(7). 730–738. 36 indexed citations
13.
Palac, Hannah, et al.. (2017). Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study. BMC Pulmonary Medicine. 17(1). 160–160. 3 indexed citations
14.
Prickett, Michelle, et al.. (2016). Aminoglycoside resistance ofPseudomonas aeruginosain cystic fibrosis results from convergent evolution in themexZgene. Thorax. 72(1). 40–47. 41 indexed citations
15.
Prickett, Michelle & Manu Jain. (2012). Gene therapy in cystic fibrosis. Translational research. 161(4). 255–264. 24 indexed citations
16.
Prickett, Michelle & Manu Jain. (2011). Pseudomonas aeruginosa Infection in Cystic Fibrosis. Clinical Pulmonary Medicine. 18(2). 53–59.
17.
Jain, Manu, Maskit Bar‐Meir, Susanna A. McColley, et al.. (2008). Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection. Translational research. 152(6). 257–264. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie Dorda Breakdown of academic impact, for papers by Nicole Mayer‐Hamblett Breakdown of academic impact, for papers by Amy Jaeger Breakdown of academic impact, for papers by Zhiqiang Zhuo Breakdown of academic impact, for papers by Marcella Blackledge Breakdown of academic impact, for papers by Mélanie Fromentin Breakdown of academic impact, for papers by Beth Hammer Breakdown of academic impact, for papers by Liliana A González Breakdown of academic impact, for papers by Nobuko Maki Breakdown of academic impact, for papers by Michael Greiner
Rankless by CCL
2026